Evotec and UCB Sign Multi-Year CNS Pharmacology Agreement

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced a collaboration with UCB to provide a broad range of in vitro pharmacology services.

Under the terms of the three-year agreement, Evotec will support UCB's in vitro pharmacology team in drug discovery projects across multiple target classes, particularly in the CNS space. Key activities will include assay development, compound profiling and mechanistic studies and will provide UCB with access to key Evotec expertise in the field of in vitro pharmacology and electrophysiology.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Through this significant collaboration focusing on CNS pharmacology, we continue to strengthen our relationship with UCB, a strategic partner of Evotec. With both teams already working closely together, we look forward to adding value to UCB's drug discovery programmes."

Dr Neil Weir, Senior Vice President of Discovery at UCB, added: "Evotec has demonstrated its scientific excellence and as such is a key partner supporting our drug discovery efforts. We welcome the addition of CNS pharmacology, where Evotec has specific expertise, to the range of activities we collaborate on."

No financial details were disclosed.

ABOUT UCB

UCB is a global biopharmaceutical company with a portfolio of small molecules and antibody based therapies for the treatment of severe immune-mediated diseases and central nervous system disorders. UCB has over 7,700 employees worldwide with research and early development scientists based in Belgium (Central Nervous System) and UK (immunology) supporting an innovative pipeline of novel therapeutics. UCB's core products are treating patients with epilepsy, rheumatoid arthritis and Parkinson's disease. UCB recognises that the identification of new and innovative protein targets remains a core challenge for the pharmaceutical industry. UCB therefore continues to invest internally, externally and through collaboration to ensure that we identify novel targets and mechanisms to tackle serious diseases. For more information please visit: www.ucb.com.

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes and with Pfizer in the field of tissue fibrosis. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161019006642/en/